Semaglutide vs Tirzepatide: How These GLP-1 Medications Compare

Two medications have fundamentally changed the landscape of medical weight management in the past few years. Semaglutide and tirzepatide are both injectable therapies that help people achieve meaningful, sustained weight loss, but they work in slightly different ways and suit different clinical profiles. Understanding how they compare can help you have a more informed conversation with your prescribing physician.

How GLP-1 Medications Work

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It signals your brain to feel full, slows the rate at which your stomach empties, and helps regulate blood sugar by stimulating insulin release. In their natural form, GLP-1 molecules break down within minutes. Both semaglutide and tirzepatide are engineered to resist that breakdown, allowing them to remain active in the body for days rather than minutes.

The key distinction is that semaglutide is a GLP-1 receptor agonist alone, while tirzepatide is a dual agonist, targeting both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone involved in appetite regulation and fat metabolism. This dual mechanism is the pharmacological basis for many of the differences seen in clinical practice.

Weight Loss Efficacy: What the Evidence Shows

Both medications deliver substantial weight reduction, but the numbers are not identical. Clinical trial programmes have consistently demonstrated the following general patterns:

• Semaglutide (at the highest approved dose for weight management) tends to produce average total body weight loss in the range of 15-17% over 68 weeks.
• Tirzepatide (at its highest studied dose) has shown average total body weight loss of approximately 20-22% over a similar timeframe.

These are population-level averages. Individual responses vary considerably based on starting weight, adherence, dietary changes, physical activity, and metabolic factors. Some patients respond dramatically to semaglutide and modestly to tirzepatide, and vice versa. The percentage difference between the two, while clinically meaningful at a population level, does not guarantee a superior outcome for any single individual.

It is also worth noting that both medications require ongoing use to maintain results. Discontinuation is associated with significant weight regain in the majority of patients, regardless of which agent is used.

Blood Sugar and Metabolic Effects

Both semaglutide and tirzepatide were originally developed for type 2 diabetes management, and both remain highly effective in that role. They lower HbA1c (a marker of long-term blood sugar control) substantially, though tirzepatide has demonstrated slightly greater reductions in head-to-head comparisons.

Beyond glucose control, both medications appear to improve several cardiometabolic risk markers:

• Reductions in triglycerides
• Improvements in blood pressure
• Reductions in waist circumference and visceral fat
• Improvements in inflammatory markers

Semaglutide has a longer track record regarding cardiovascular outcomes, with dedicated trial data showing a reduction in major adverse cardiovascular events in people with established heart disease. Cardiovascular outcome data for tirzepatide are still maturing, though early signals are encouraging.

Side Effect Profiles

The side effect profiles of semaglutide and tirzepatide overlap considerably because they share the GLP-1 pathway. The most common adverse effects are gastrointestinal:

• Nausea (the most frequently reported, especially during dose escalation)
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort

For most patients, these symptoms are mild to moderate and diminish as the body adjusts over several weeks. Slow, stepwise dose titration is the primary strategy for minimising gastrointestinal distress with either medication.

Some comparative data suggest that tirzepatide may cause slightly more nausea at higher doses, though discontinuation rates due to side effects are broadly similar between the two. Serious adverse events, including pancreatitis and gallbladder disease, are rare with both agents but warrant awareness.

Neither medication should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. This is a shared contraindication based on preclinical findings.

Dosing and Administration

Both semaglutide and tirzepatide are administered as once-weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. Both use pre-filled pen devices that are relatively straightforward to use at home.

• Semaglutide for weight management is titrated from a starting dose of 0.25 mg weekly, escalating over approximately 16-20 weeks to a maintenance dose of 2.4 mg weekly.
• Tirzepatide starts at 2.5 mg weekly and escalates over a similar period, with maintenance doses ranging from 5 mg to 15 mg weekly depending on individual response and tolerability.

The gradual escalation schedule exists specifically to allow the gastrointestinal system to adapt. Skipping dose steps or escalating too quickly is one of the most common reasons patients experience intolerable side effects.

Semaglutide is also available in an oral formulation for type 2 diabetes, though the oral form is not currently approved at the doses used for weight management in most jurisdictions.

Cost and Accessibility in the EU

Availability and reimbursement vary significantly across EU member states. Semaglutide has been on the market longer and generally has broader regulatory approval and reimbursement pathways for both diabetes and weight management indications. Tirzepatide approval for weight management is newer in the EU, and reimbursement frameworks are still being established in many countries.

Out-of-pocket costs for both medications remain substantial where they are not reimbursed. Supply constraints have also affected both agents at various points, though the situation has been improving as manufacturing capacity expands.

A telehealth consultation can help clarify what is available and potentially reimbursable in your specific country and clinical situation, saving you time navigating complex regulatory landscapes.

How to Choose Between Them

There is no universal answer to which medication is "better." The right choice depends on a combination of clinical and practical factors:

• Degree of weight loss needed. For patients who need maximal weight reduction, tirzepatide's slightly higher average efficacy may be a relevant consideration.
• Diabetes status. Both are excellent options for patients with type 2 diabetes. Tirzepatide may offer marginally better glycaemic control for some individuals.
• Cardiovascular history. Semaglutide currently has stronger cardiovascular outcome data, which may influence prescribing decisions for patients with established heart disease.
• Tolerability. If a patient has trialled one agent and found the side effects unmanageable despite proper titration, switching to the other is a reasonable clinical strategy.
• Availability and cost. Practical access matters. The medication you can obtain consistently and afford is more effective than one you cannot.
• Prescriber experience. Your physician's familiarity with dosing, titration, and managing side effects for a given agent can meaningfully influence your outcome.

This is not a decision to make based on social media testimonials or headline comparisons. It requires a thorough clinical assessment, including a review of your medical history, current medications, metabolic markers, and treatment goals.

The Role of Telehealth in GLP-1 Treatment

GLP-1 therapy requires ongoing medical supervision, not just an initial prescription. Dose titration, side effect management, blood work monitoring, and periodic reassessment of treatment goals all benefit from regular clinician contact. Telehealth platforms are well-suited to this model of care, offering convenient follow-up consultations without the need for repeated in-person visits.

That said, telehealth works best as part of a broader care strategy. Certain assessments, such as baseline blood panels, imaging, or evaluation of new symptoms, may still require in-person visits with your local healthcare provider.

---

This article is for informational purposes only and does not constitute personalised medical advice. GLP-1 receptor agonists are prescription medications that require clinical assessment before initiation. If you are considering semaglutide or tirzepatide for weight management, consult a licensed physician who can evaluate your individual health profile and recommend an appropriate treatment plan. AETHERA Health provides EU-licensed telehealth consultations and can connect you with qualified prescribers.